PDB40 COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES MELLITUS IN POLAND
Abstract
Authors
D Szmurlo A Gurda-Duda P Rys J Rutkowski I Skrzekowska-Baran R Plisko M Wladysiuk